Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy

被引:128
|
作者
Ding, Yingyue [1 ,2 ,3 ]
Wang, Yixin [1 ,2 ,3 ]
Hu, Quanyin [1 ,2 ,3 ]
机构
[1] Univ Wisconsin Madison, Sch Pharm, Pharmaceut Sci Div, Madison, WI 53705 USA
[2] Univ Wisconsin Madison, Sch Med & Publ Hlth, Carbone Canc Ctr, Madison, WI USA
[3] Univ Wisconsin Madison, Sch Pharm, Wisconsin Ctr NanoBioSyst, Madison, WI USA
来源
EXPLORATION | 2022年 / 2卷 / 03期
关键词
cancer; cell; delivery barriers; drug delivery; immunotherapy; FIBROBLAST ACTIVATION PROTEIN; MEMBRANE-COATED NANOPARTICLES; RED-BLOOD-CELLS; CAR-T CELLS; TUMOR MICROENVIRONMENT; DRUG-DELIVERY; EXTRACELLULAR VESICLES; THERAPY; COMBINATION; IMMUNITY;
D O I
10.1002/EXP.20210106
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Immunotherapy strategies that use cell-based delivery systems have sparked much interest in the treatment of malignancies, owing to their high biocompatibility, excellent tumor targeting capability, and unique biofunctionalities in the tumor growth process. A variety of design principles for cell-based immunotherapy, including cell surface decoration, cell membrane coating, cell encapsulation, genetically engineered cell, and cell-derived exosomes, give cancer immunotherapy great potential to improve therapeutic efficacy and reduce adverse effects. However, the treatment efficacy of cell-based delivery methods for immunotherapy is still limited, and practical uses are hampered due to complex physiological and immunological obstacles, such as physical barriers to immune infiltration, immunosuppressive tumor microenvironment, upregulation of immunosuppressive pathways, and metabolic restriction. In this review, we present an overview of the design principles of cell-based delivery systems in cancer immunotherapy to maximize the therapeutic impact, along with anatomical, metabolic, and immunological impediments in using cell-based immunotherapy to treat cancer. Following that, a summary of novel delivery strategies that have been created to overcome these obstacles to cell-based immunotherapeutic delivery systems is provided. Also, the obstacles and prospects of next-step development of cell-based delivery systems for cancer immunotherapy are concluded in the end.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer
    Ni, Ling
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [22] Nano-drug delivery systems for T cell-based immunotherapy
    Li, Rui
    Chen, Zhimin
    Li, Juyi
    Dai, Zhifei
    Yu, Yingjie
    NANO TODAY, 2022, 46
  • [23] Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy
    Lim, Seungho
    Park, Jooho
    Shim, Man Kyu
    Um, Wooram
    Yoon, Hong Yeol
    Ryu, Ju Hee
    Lim, Dong-Kwon
    Kim, Kwangmeyung
    THERANOSTICS, 2019, 9 (25): : 7906 - 7923
  • [24] Recent clinical development of dendritic cell-based immunotherapy for prostate cancer
    Rini, B
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (11) : 1729 - 1734
  • [25] Cell-Intrinsic barriers of T Cell-Based Immunotherapy
    Ghoneim, Hazem E.
    Zamora, Anthony E.
    Thomas, Paul G.
    Youngblood, Ben A.
    TRENDS IN MOLECULAR MEDICINE, 2016, 22 (12) : 1000 - 1011
  • [26] Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer
    Nia, Giti Esmail
    Nikpayam, Elahe
    Farrokhi, Molood
    Bolhassani, Azam
    Meuwissen, Ralph
    MOLECULAR THERAPY ONCOLOGY, 2024, 32 (01):
  • [27] Cell-based immunotherapy in oesophageal cancer
    Lahouty, Masoud
    Soleymanzadeh, Amirhossein
    Kazemi, Sama
    Saadati-Maleki, Haniyeh
    Masoudi, Sanaz
    Ghasemi, Arash
    Kazemi, Tohid
    Mehranfar, Sahar
    Fadaee, Manouchehr
    JOURNAL OF DRUG TARGETING, 2025,
  • [28] Dendritic cell-based immunotherapy of cancer
    Zitvogel, L
    Angevin, E
    Tursz, T
    ANNALS OF ONCOLOGY, 2000, 11 : 199 - 205
  • [29] NK cell-based cancer immunotherapy
    Stagg, John
    Smyth, Mark J.
    DRUG NEWS & PERSPECTIVES, 2007, 20 (03) : 155 - 163
  • [30] B Cell-Based Cancer Immunotherapy
    Wennhold, Kerstin
    Shimabukuro-Vornhagen, Alexander
    von Bergwelt-Baildon, Michael
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2019, 46 (01) : 36 - 46